Monitor for Health Canada's Notice of Compliance as the next catalyst; absence of approval delays potential Canadian market entry and near-term revenue. The receipt of DINs suggests progress, but not final approval.
RDY drugs
RDY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 24 $13.67entry
- T+1 · 7mo ago +2.19%α +2.03% · $13.97
- T+5 · 7mo ago −0.22%α −1.13% · $13.64
- T+20 · 6mo ago −0.88%α −4.90% · $13.55
- T+60 · 4mo ago −8.12%α −13.20% · $12.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's Laboratories confirmed it has not yet received Health Canada approval for its Semaglutide Injection, though it has obtained Drug Identification Numbers (DINs). The company remains engaged with regulators and plans to launch the product upon approval. No additional material information requiring disclosure was reported.
Key Facts
- Company has not yet received Health Canada approval (Notice of Compliance) for Semaglutide Injection.
- Drug Identification Numbers (DINs) for Semaglutide Injection were received on April 22, 2026.
- Filing is in response to a media report and confirms limited regulatory progress without new financial or clinical data.
- No material event or information beyond this update requires disclosure under SEBI rules.
Financial Impact
Undisclosed; regulatory delay may impact near-term revenue expectations for Semaglutide in Canada, but no financial figures provided.
Risk Factors
- Regulatory delay risk for Semaglutide Injection in Canada
- Market uncertainty due to lack of timeline for final approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000261 |
| Document: 0001575872-26-000261-index.html | 0001575872-26-000261 |
| Document: 0001575872-26-000261.txt | 0001575872-26-000261 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers